# EPCORE™ NHL-2 (NCT04663347)

> Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04663347
- Phase: PHASE1, PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Genmab
- Conditions: Diffuse Large B-Cell Lymphoma; Follicular Lymphoma
- Interventions: rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; rituximab and lenalidomide; rituximab and bendamustine; rituximab, cytarabine, dexamethasone, and oxaliplatin/carboplatin; gemcitabine and oxaliplatin; Epcoritamab; rituximab, cyclophosphamide, reduced dose of doxorubicin, vincristine, and prednisone; Lenalidomide; rituximab, ifosfamide, carboplatin, and etoposide phosphate; Epcoritamab; Epcoritamab; Epcoritamab; Epcoritamab; Epcoritamab; Epcoritamab; Epcoritamab; Rituximab and Lenalidomide; Epcoritamab
- Enrollment: 543
- Primary outcome: Part 1: Number of Participants With Dose limiting Toxicities (DLTs)
- Primary outcome: Part 1 and Part 2 (Arms 1-5, 7 and 10): Number of Participants With Adverse Events (AEs)
- Primary outcome: Part 2 (Except Arm 7): Overall Response Rate (ORR)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- Podcasts: 1
- X threads: 1
- Bluesky threads: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=epcore-nhl-2-nct04663347